Results 171 to 180 of about 1,271,462 (341)

Integration of ROSE cytology and serum tumor markers for rapid subtyping of lung cancer. [PDF]

Sci Rep
Zhao Z, Zou Q, Fang Y, Zhao D, Li Y, Li R, Jiang J, Ge X.   +7 more
europepmc   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

379. Analysis of tumor marker (CA15-3, CEA) on breast cancer patient with bone metastasis (scintigram)

, 1990
Toshihide Ise, Eiichiroh Nemoto, Atsushi Seto, Takatoshi Okumura   +3 more
openalex   +2 more sources

Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers. [PDF]

PLoS One
Li Y, Wu J, Long M, Zeng T, Jiang D.
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Serum Ca 15.3 Levels in Patients with Non-Tumoral Diseases, and Establishment of a Threshold for Tumoral Activity. Results in 1219 Patients

The International Journal of Biological Markers, 1986
Alvaro Ruibal, José Genollá, Mariona Rosell, José María Gris, Ramón Colomer   +4 more
doaj   +1 more source

Editorial: Bio-Inspired Nanomaterials in Surface Engineering and Bioapplications

Frontiers in Chemistry, 2022
Yun Jun Yang, Zhong Feng Gao, Zhong Feng Gao   +2 more
doaj   +1 more source

Clinical effects of debulking surgery combined with neoadjuvant chemotherapy in treating ovarian cancer and its influence on tumor markers and immune function

Huijuan Yan, Weiwei Wang, Shengchao Wang, Chunmei Yan, Li Zhu   +4 more
openalex   +2 more sources

Study of serum tumor markers in the early diagnosis of pancreatic cancer. [PDF]

World J Gastrointest Oncol
Deng QX, Tang XL, Yuan GJ, Jian Q, Chen XH, Wu LJ.   +5 more
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source